Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle

Inclusion Criteria: * RESIDENT OF CANADA * Premenopausal * Age 40 years or less at the time of enrollment * At risk of a poor ovarian response defined as: either \<5 oocytes or \<8 follicles in a previous cycle, FSH \> 10 IU/L, AMH \< 1 pg/ml , antral follicle count less or equal to 8 or previous IVF cancellation * Primary infertility or secondary * Not previously undertaken a cycle that was included in this study Exclusion Criteria: * Simultaneous participation in another clinical trial * Body mass index (BMI) \> 38 kg/m2 * Early follicular phase (day 2-4) serum FSH level \> 20 mIU/ml * Any contraindication to being pregnant and carrying a pregnancy to term * Contraindication for the use of Estrace® , Suprefact®, Menopur®, Bravelle®, hCG, and luteal phase support medication * Any ovarian or abdominal abnormality that may interfere with adequate transvaginal ultrasound evaluation * Administration of any investigational drugs within three months prior to study enrollment * Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study * Positive results of screening of either partner for HIV antibodies, Hepatitis B (other than for surface antibodies present after vaccination) or Hepatitis C * Unwillingness to give written informed consent